Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Brinson · SciRah

Researcher profile · Semantic Scholar

C. Brinson

Share profile

C. Brinson — researcher profile on SciRah

h-index: 29
Works: 75
Citations: 4,947

Most-cited papers

Brief Report
D. Wohl, S. Oka, N. Clumeck, A. Clarke +15 more
2024International Conference on Numerical Simulation of Optoelectronic Devices1,291 citations Open access
Semantic Scholar
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.
Anil K Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, Manuel Crespo Casal +18 more
2021New England Journal of Medicine872 citations Open access
Semantic Scholar
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
C. Orkin, K. Arastéh, Miguel Górgolas Hernández-Mora, V. Pokrovsky +23 more
2020New England Journal of Medicine368 citations Open access
Semantic Scholar
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
J. Llibre, Chien-Ching Hung, C. Brinson, F. Castelli +10 more
2018The Lancet334 citations
Semantic Scholar
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Kenneth H. Mayer, J. Molina, Melanie Thompson, Peter L. Anderson +20 more
2020The Lancet328 citations Open access
Semantic Scholar
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
P. Cahn, J. S. Madero, J. Arribas, A. Antinori +205 more
2019The Lancet323 citations Open access
Semantic Scholar
Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Anil K Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, Manuel Crespo Casal +16 more
2022Journal of the American Medical Association (JAMA)254 citations Open access
Semantic Scholar
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons.
Colleen F Kelley, Maribel Acevedo-Quiñones, Allison Agwu, A. Avihingsanon +51 more
2024New England Journal of Medicine243 citations
Semantic Scholar
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
D. Margolis, C. Brinson, Graham H. R. Smith, J. de Vente +12 more
2015Lancet. Infectious Diseases (Print)196 citations
Semantic Scholar
Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain
D. Kerrigan, A. Mantsios, M. Górgolas, M. Montes +8 more
2018PLoS ONE154 citations Open access
Semantic Scholar
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
J. Molina, D. Ward, I. Brar, A. Mills +11 more
2018The Lancet HIV150 citations
Semantic Scholar
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
C. Orkin, S. Oka, P. Philibert, C. Brinson +23 more
2021The Lancet HIV147 citations
Semantic Scholar
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.
J. Gallant, E. Daar, F. Raffi, C. Brinson +12 more
2016The Lancet HIV138 citations
Semantic Scholar
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
D. Wohl, Y. Yazdanpanah, A. Baumgarten, A. Clarke +10 more
2019The Lancet HIV133 citations Open access
Semantic Scholar
Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study
B. Trottier, J. Lake, K. Logue, C. Brinson +7 more
2017Antiviral Therapy105 citations
Semantic Scholar
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
P. Sax, E. Dejesus, G. Crofoot, D. Ward +10 more
2017The Lancet HIV91 citations
Semantic Scholar
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
C. Orkin, E. Dejesus, P. Sax, J. Arribas +17 more
2020The Lancet HIV81 citations Open access
Semantic Scholar
Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate–Based Single-Tablet Regimens
A. Mills, C. Cohen, E. Dejesus, C. Brinson +7 more
2013HIV Clinical Trials78 citations Open access
Semantic Scholar
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy
Devi SenGupta, C. Brinson, E. Dejesus, A. Mills +20 more
2021Science Translational Medicine69 citations
Semantic Scholar
Safety, Efficacy, and Pharmacokinetics of TBR-652, a CCR5/CCR2 Antagonist, in HIV-1–Infected, Treatment-Experienced, CCR5 Antagonist–Naive Subjects
J. Lalezari, J. Gathe, C. Brinson, M. Thompson +6 more
2011Journal of Acquired Immune Deficiency Syndromes66 citations
Semantic Scholar
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B–Coinfected Adults
J. Gallant, J. Brunetta, G. Crofoot, P. Benson +8 more
2016Journal of Acquired Immune Deficiency Syndromes63 citations Open access
Semantic Scholar
Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials
F. Raffi, A. Rachlis, C. Brinson, K. Arastéh +9 more
2015AIDS (London)61 citations Open access
Semantic Scholar
Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.
M. Glesby, W. Watson, C. Brinson, R. Greenberg +9 more
2015Journal of Infectious Diseases61 citations Open access
Semantic Scholar
Vesatolimod, a toll-like receptor 7 agonist, induces immune activation in virally suppressed adults with HIV-1.
S. Riddler, M. Para, C. Benson, A. Mills +21 more
2020Clinical Infectious Diseases58 citations Open access
Semantic Scholar
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial.
O. Ogbuagu, S. Segal-maurer, W. Ratanasuwan, A. Avihingsanon +11 more
2023The Lancet HIV56 citations
Semantic Scholar
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.
J. Lalezari, G. Latiff, C. Brinson, J. Echevarría +12 more
2015The Lancet HIV55 citations
Semantic Scholar
Early Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab
Anil K Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, M. Casal +18 more
2021medRxiv54 citations Open access
Semantic Scholar
Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials
D. Hagins, C. Orkin, E. Daar, A. Mills +15 more
2018HIV Medicine54 citations Open access
Semantic Scholar
SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen
R. Campo, E. Dejesus, U. Bredeek, K. Henry +11 more
2013Clinical Infectious Diseases47 citations Open access
Semantic Scholar
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy
A. Mills, G. Richmond, C. Newman, O. Osiyemi +12 more
2021AIDS (London)30 citations Open access
Semantic Scholar
Switching From Twice-Daily Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine to Once-Daily Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed, HIV-1–Infected Subjects: 48 Weeks Data
A. Mills, G. Crofoot, R. Ortiz, B. Rashbaum +9 more
2014HIV Clinical Trials25 citations Open access
Semantic Scholar
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis
P. Rossing, G. Bakris, V. Perkovic, R. Pratley +395 more
2025Diabetes Care22 citations Open access
Semantic Scholar
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19
F. Isa, E. Forleo-Neto, Jonathan Meyer, Wen-Jun Zheng +26 more
2022International Journal of Infectious Diseases21 citations Open access
Semantic Scholar
The role of human papillomavirus deoxyribonucleic acid assay and repeated cervical cytologic examination in the detection of cervical intraepithelial neoplasia among human immunodeficiency virus–infected women
J. Cohn, S. Gagnon, M. Spence, D. D. Harrison +5 more
200121 citations
Semantic Scholar
Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment
E. Wilkins, C. Cohen, B. Trottier, S. Esser +7 more
2016AIDS Care20 citations
Semantic Scholar
Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.
A. E. Colson, G. Crofoot, P. Ruane, M. Ramgopal +19 more
2025Annals of Internal Medicine17 citations
Semantic Scholar
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results
D. Wohl, S. Oka, N. Clumeck, A. Clarke +15 more
2016Journal of Acquired Immune Deficiency Syndromes16 citations Open access
Semantic Scholar
Lenacapavir Plus Two Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab.
J. Eron, Paul P. Cook, M. Mehrotra, Hai-Lin Huang +9 more
2025Journal of Infectious Diseases13 citations
Semantic Scholar
The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single‐arm, open‐label study of etravirine and darunavir/ritonavir as dual therapy in HIV‐1‐infected early treatment‐experienced subjects
PJ Ruane, C. Brinson, M. Ramgopal, R. Ryan +4 more
2015HIV Medicine13 citations Open access
Semantic Scholar
Repeat Subcutaneous Administration of REGEN-COV(R) in Adults is Well-Tolerated and Prevents the Occurrence of COVID-19
F. Isa, E. Forleo-Neto, J. Meyer, W. Zheng +27 more
2021medRxiv10 citations Open access
Semantic Scholar
Effect of the Neutralizing SARS-CoV-2 Antibody Sotrovimab in Preventing Progression of COVID-19: A Randomized Clinical Trial
Anil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, M. Crespo +16 more
2021medRxiv10 citations Open access
Semantic Scholar
Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials
E. Lathouwers, E. Y. Wong, K. Brown, B. Baugh +159 more
2019AIDS Research and Human Retroviruses10 citations Open access
Semantic Scholar
Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV
E. Daar, C. Orkin, Paul E. Sax, D. Hagins +10 more
2025AIDS Research and Therapy9 citations Open access
Semantic Scholar
LB4. A Phase 3, Randomized, Controlled Clinical Trial of Bictegravir in a Fixed-Dose Combination, B/F/TAF, vs. ABC/DTG/3TC in Treatment-Naïve Adults at Week 96
D. Wohl, Y. Yazdanpanah, A. Baumgarten, A. Clarke +11 more
2018Open Forum Infectious Diseases8 citations Open access
Semantic Scholar
Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
P. Sax, E. Dejesus, G. Crofoot, D. Ward +7 more
2018AIDS (London)7 citations Open access
Semantic Scholar
Very-Low-Level Viremia, Inflammatory Biomarkers, and Associated Baseline Variables: Three-Year Results of the Randomized TANGO Study
Ruolan Wang, Mark Underwood, J. Llibre, Enrique Bernal Morell +11 more
2023Open Forum Infectious Diseases6 citations Open access
Semantic Scholar
HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 sub-group analysis
C. Brinson, J. Lalezari, Latiff H Gulam, M. Thompson +6 more
2014Journal of the International AIDS Society6 citations Open access
Semantic Scholar
The role of human papillomavirus deoxyribonucleic acid assay and repeated cervical cytologic examination in the detection of cervical intraepithelial neoplasia among human immunodeficiency virus-infected women. Cervical Disease Study Group of the American Foundation for AIDS Research Community Based
J. Cohn, S. Gagnon, M. Spence, D. D. Harrison +5 more
2001American Journal of Obstetrics and Gynecology6 citations
Semantic Scholar
Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 Treatment.
J. Rockstroh, M. Ramgopal, Adrian Curran Fàbregas, M. Hedgcock +21 more
2026New England Journal of Medicine5 citations
Semantic Scholar
Vesatolimod (GS-9620) is safe and pharmacodynamically active in HIV-infected individuals
S. Riddler, M. Para, C. Benson, A. Mills +15 more
2019Journal of virus eradication5 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

E. Dejesus×13
Invite
E. Dejesus — researcher profile on SciRah
A. Mills×12
Invite
A. Mills — researcher profile on SciRah
M. Ramgopal×11
Invite
M. Ramgopal — researcher profile on SciRah
A. Cheng×10
Invite
A. Cheng — researcher profile on SciRah

×8

Invite

A. Clarke — researcher profile on SciRah

Invite

C. Orkin — researcher profile on SciRah

Invite

P. Benson — researcher profile on SciRah

Invite

G. Crofoot — researcher profile on SciRah

Invite

M. Thompson — researcher profile on SciRah

Sean E. Collins×6

Invite

Sean E. Collins — researcher profile on SciRah

Invite

D. Brainard — researcher profile on SciRah

Invite

D. Hagins — researcher profile on SciRah